Oncology Med Begins Commissioning of Meadville (PA) Medical Center's New Comprehensive Cancer Treatment Facility
2008年2月5日 - 9:00PM
Marketwired
PITTSBURGH, PA , a Pittsburgh-based cancer treatment solutions
group, announced today that it has begun the acceptance testing on
the linear accelerator for its new multi-year exclusive contract
with the Meadville Medical Center in Meadville, Pennsylvania.
Oncology Med is providing Meadville's state of the art full service
cancer treatment center with a complete range of medical physics
support to include radiation shielding design and analysis,
equipment acceptance and commissioning and on-going medical physics
consulting services. Oncology Med was selected by Meadville over
several competitors.
"Once completed, our Company will be able to provide a variety
of additional medical physics services which will result in
increased revenue results beginning in April 2008 and continuing
throughout the term of our multi-year contract with Meadville
Medical Center. Our continued on time achievements of goals and
initiatives which were laid out at the end of 2007 will only result
in increased revenues and new client opportunities as we go forward
in our fiscal year 2008," stated William Walker, Ph.D., Oncology
Med's CEO and founder.
"We are excited to have been made a part of this innovative
project and are anticipating completion of the acceptance and
commissioning phase on time and within budget. The multi-million
dollar linear accelerator treatment unit is the heart of the
facility and its reliability and accuracy are paramount concerns to
the cancer center. Oncology Meds professional medical physics
team's goal is to have the accelerator ready for clinical tests by
early April 2008."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: Oncology Med, Inc. Email
Contact
Bellatora (PK) (USOTC:ECGR)
過去 株価チャート
から 4 2024 まで 5 2024
Bellatora (PK) (USOTC:ECGR)
過去 株価チャート
から 5 2023 まで 5 2024
